BioMarin Pharma (NASDAQ: BMRN) announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111 (vosoritide) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Canaccord Genuity Raises Price Target on BioMarin Pharma (BMRN) Following BMN-111 Data June 18, 2015 10:03 AM BioMarin's (BMRN) Price Target Raised to $156 at Deutsche BankJune 18, 2015 8:19 AM BioMarin (BMRN) PT Lifted to 'Street High' $170 at SunTrust Amid Growing Confidence in Dwarfism Drug BMN 111June 18, 2015 7:51 AM BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC June 18, 2015 7:35 AM BioMarin Pharmaceutical (BMRN) PT Raised to $147 at Piper Jaffray Following Positive BMN-111 UpdateJune 18, 2015 7:02 AM BioMarin (BMRN) PT Raised to $143 at Leerink Partners as BMN-111 Meets Primary EndpointJune 18, 2015 6:28 AM BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 StudyJune 17, 2015 4:01 PM Form 8-K BIOMARIN PHARMACEUTICAL For: Jun 09June 15, 2015 5:12 PM BioMarin CEO Jean-Jacques Bienaime Awarded EY Entrepreneur Of The Year(R) 2015 Award in Northern California in Health and Life SciencesJune 15, 2015 8:31 AM